Altamira and Univercells partner to test mRNA vaccine delivery By Investing.com
[ad_1]
© Reuters.
HAMILTON, BERMUDA – Altamira Therapeutics Ltd. (NASDAQ:), a specialist in RNA delivery technology, has announced a collaboration with Univercells Group to test a novel mRNA vaccine delivery using Altamira’s SemaPhore nanoparticle platform. Univercells, known for developing and manufacturing biologics efficiently, will conduct in vitro and in vivo tests with the potential to enter a commercial agreement for producing mRNA vaccines if successful.
The SemaPhore platform is designed to deliver mRNA safely and effectively, addressing the challenges of mRNA degradation and side effects associated with current delivery vehicles. Covadonga Pañeda, PhD, COO at Altamira, expressed optimism about SemaPhore’s potential to improve mRNA vaccine delivery by reducing dosage and enhancing tolerability.
Univercells’ CTO, José Castillo, PhD, emphasized the transformative impact of mRNA in medicine, highlighting the need for advancements in delivery platforms to maximize the technology’s efficacy and affordability.
Both companies aim to leverage their expertise to make mRNA vaccines more accessible and effective.
The information for this article is based on a press release statement from Altamira Therapeutics Ltd.
InvestingPro Insights
As Altamira Therapeutics Ltd. (NASDAQ:CYTO) embarks on this promising collaboration with Univercells Group, investors are closely monitoring the company’s financial health and stock performance. According to the latest data from InvestingPro, Altamira’s market capitalization stands at a modest $5.33 million USD. The company’s financial metrics reflect the challenges faced by many early-stage biotech firms, with a negative revenue growth of -66.09% over the last twelve months as of Q2 2023, and a gross profit margin of -285.58%, underscoring the significant costs associated with research and development in this sector.
Despite these hurdles, there are positive signals in the InvestingPro Tips that could suggest potential for future growth. Analysts expect net income to grow this year, and sales growth is also anticipated in the current year. These projections may be buoyed by the innovative potential of Altamira’s SemaPhore nanoparticle platform and its applications in mRNA vaccine delivery. However, it’s important to note that the company’s stock has been trading near its 52-week low and has experienced high price volatility, which is common in the biotech industry where stock prices can be sensitive to news and developments in clinical trials and partnerships.
Investors considering Altamira Therapeutics as an investment opportunity can find additional insights with InvestingPro. There are more tips available, including analysis on the company’s short-term obligations versus liquid assets, industry positioning, and profitability predictions. To enrich your investment decision-making, use coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription at InvestingPro, where you can access these valuable tips and more.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
[ad_2]
Source link
© Reuters.
HAMILTON, BERMUDA – Altamira Therapeutics Ltd. (NASDAQ:), a specialist in RNA delivery technology, has announced a collaboration with Univercells Group to test a novel mRNA vaccine delivery using Altamira’s SemaPhore nanoparticle platform. Univercells, known for developing and manufacturing biologics efficiently, will conduct in vitro and in vivo tests with the potential to enter a commercial agreement for producing mRNA vaccines if successful.
The SemaPhore platform is designed to deliver mRNA safely and effectively, addressing the challenges of mRNA degradation and side effects associated with current delivery vehicles. Covadonga Pañeda, PhD, COO at Altamira, expressed optimism about SemaPhore’s potential to improve mRNA vaccine delivery by reducing dosage and enhancing tolerability.
Univercells’ CTO, José Castillo, PhD, emphasized the transformative impact of mRNA in medicine, highlighting the need for advancements in delivery platforms to maximize the technology’s efficacy and affordability.
Both companies aim to leverage their expertise to make mRNA vaccines more accessible and effective.
The information for this article is based on a press release statement from Altamira Therapeutics Ltd.
InvestingPro Insights
As Altamira Therapeutics Ltd. (NASDAQ:CYTO) embarks on this promising collaboration with Univercells Group, investors are closely monitoring the company’s financial health and stock performance. According to the latest data from InvestingPro, Altamira’s market capitalization stands at a modest $5.33 million USD. The company’s financial metrics reflect the challenges faced by many early-stage biotech firms, with a negative revenue growth of -66.09% over the last twelve months as of Q2 2023, and a gross profit margin of -285.58%, underscoring the significant costs associated with research and development in this sector.
Despite these hurdles, there are positive signals in the InvestingPro Tips that could suggest potential for future growth. Analysts expect net income to grow this year, and sales growth is also anticipated in the current year. These projections may be buoyed by the innovative potential of Altamira’s SemaPhore nanoparticle platform and its applications in mRNA vaccine delivery. However, it’s important to note that the company’s stock has been trading near its 52-week low and has experienced high price volatility, which is common in the biotech industry where stock prices can be sensitive to news and developments in clinical trials and partnerships.
Investors considering Altamira Therapeutics as an investment opportunity can find additional insights with InvestingPro. There are more tips available, including analysis on the company’s short-term obligations versus liquid assets, industry positioning, and profitability predictions. To enrich your investment decision-making, use coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription at InvestingPro, where you can access these valuable tips and more.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
About The Author
